Five-factor prognostic index for chronic lymphocytic leukemia using TP53, IGHV, beta-2 microglobulin, stage, and age.
Waiting For Required Inputs
Complete the required fields to generate the oncology interpretation.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
Primary Use
Baseline prognostic stratification in CLL
Highlights TP53-disrupted and IGHV-unmutated biology
Section 2
Formula & Logic
Clinical Inputs
Age
years
Beta-2 microglobulin
mg/L
Advanced stage (Binet B/C or Rai I-IV)
Binary clinical feature
IGHV unmutated
Binary clinical feature
TP53 mutation or del(17p)
Binary clinical feature
Interpretive Logic
Age > 65 years adds 1 point.
Advanced clinical stage adds 1 point.
Beta-2 microglobulin > 3.5 mg/L adds 2 points.
IGHV unmutated adds 2 points.
TP53 aberration adds 4 points.
Section 3
Pearls/Pitfalls
Result Bands
Low
0-1 points
Intermediate
2-3 points
High
4-6 points
Very High
7-10 points
Section 4
Next Steps
Suggested Next Steps
01
Use with full staging, cytogenetics, and treatment indication criteria.
02
Prioritize TP53-aware treatment planning when high-risk biology is present.
Section 5
Evidence Appraisal
Evidence Base
Five-factor prognostic index for chronic lymphocytic leukemia using TP53, IGHV, beta-2 microglobulin, stage, and age.
OpiCalc Medical Oncology Module • Haematological Malignancies. 2026;Logic implemented from widely used contemporary oncology classification, prognostic, and response-assessment frameworks.
Section 6
Literature
Context
CLL-IPI is included in the oncology module as a structured decision-support tool for haematological malignancies workflows.
